These results suggest a promising beneficial effect of GLP-1R agonists on endometrial cancer risk and on progression, even in the absence of obesity, although much remains to be investigated, especially regarding the potential of combining GLP-1R agonists with standard therapies (76). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.